← All stocks

Cullinan Therapeutics, Inc.

CGEM Net buying

CIK 0001789972 #2364 in the set updated 17 Sep 2026

Bought (12 mo)

$13.32M

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$2.51M

$252.08K on a plan · $1.33M straight out of an exercise

Sold at will

$926.59K

12 of 28 sales

Net

+$10.81M

+$12.40M against sales at will

By person

7 insiders · 36 transactions

12.0×

Nadim Ahmed holds 12.0 times base salary in stock. $8.43M of shares against $698.48K in salary for 2025.

Salary from the company's own proxy. The shares are what Nadim Ahmed last reported holding, valued at $21.57, the price Common Stock was last bought or sold at on the open market here, on 8 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Lynx1 Capital Management LP entity

10% owner

$13.32M (8)

—

+$13.32M

8,963,500

13.93%

$193.34M

+26.4%

Michaelson Jennifer

Chief Scientific Officer

—

$1.62M (18) scheduled

−$1.62M

158,844

0.2468%

$3.43M

+34.7%

AHMED NADIM

President and CEO

—

$517.99K (3)

−$517.99K

390,803

0.6073%

$8.43M

+43.9%

Jones Jeffrey Alan

Chief Medical Officer

—

$178.95K (3)

−$178.95K

159,968

0.2486%

$3.45M

+34.8%

SUMER JACQUELYN L

Chief Legal Officer

—

$136.72K (3)

−$136.72K

130,559

0.2029%

$2.82M

+35.8%

Fenton Mary Kay

Chief Financial Officer

—

$59.90K (1)

−$59.90K

127,921

0.1988%

$2.76M

+6,293%

Savill Corrine

Chief Business Officer

—

240,990

0.3745%

$5.20M

+18.4%

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 42

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 3

Sales on a Rule 10b5-1 plan 8

Sales straight out of an exercise 8

Sales at will 12

Transactions with no price 0

Shares from compensation/vesting 184,288

History held since 11 Jan 2021